Site Search

Sahil Parikh, MD, Dierk Scheinert, MD, and Edward Choke, MD

Andrej Schmidt, MD (Sponsored by Cydar Medical)

Orlando, FL, March 31st, 2020 - Manufacturers of

William R. Hiatt, MD, Professor of Medicine/Cardiology at the University of Colorado School of Medicine, and Chief Science Officer at CPC Clinical Research, Denver, Colorado.

DOAC more effective in lowering risk of post-procedure VTE without increasing bleeding risk WASHINGTON (Mar 29, 2020) - The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people…

Subgroup analysis suggests concomitant use of clopidogrel may not play role after PAD revascularizations WASHINGTON (Mar 29, 2020) - The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner…

No increase in the risk of major bleeding seen, including for gastrointestinal cancers WASHINGTON (Mar 29, 2020) - For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given…

No serious adverse effects seen after three months of follow-up WASHINGTON (Mar 29, 2020) - Three months after undergoing renal denervation (RDN)—a procedure that delivers energy to overactive nerves leading to the kidney to decrease their…